

RESEARCH ARTICLE

Open Access

The dopamine β -hydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis Project

Onofre Combarros^{1*}, Donald R Warden², Naomi Hammond³, Mario Cortina-Borja⁴, Olivia Belbin⁵, Michael G Lehmann², Gordon K Wilcock⁶, Kristelle Brown⁵, Patrick G Kehoe⁷, Rachel Barber⁷, Eliecer Coto⁸, Victoria Alvarez⁸, Panos Deloukas³, Rhian Gwilliam³, Reinhard Heun^{9,10}, Heike Kölsch⁹, Ignacio Mateo¹, Abderrahim Oulhaj¹¹, Alejandro Arias-Vásquez^{12,13}, Maaïke Schuur^{12,14}, Yurii S Aulchenko¹², M Arfan Ikram¹², Monique M Breteler¹², Cornelia M van Duijn¹², Kevin Morgan⁵, A David Smith², Donald J Lehmann²

Abstract

Background: The loss of noradrenergic neurones of the locus coeruleus is a major feature of Alzheimer's disease (AD). Dopamine β -hydroxylase (DBH) catalyses the conversion of dopamine to noradrenaline. Interactions have been reported between the low-activity -1021T allele (rs1611115) of *DBH* and polymorphisms of the pro-inflammatory cytokine genes, *IL1A* and *IL6*, contributing to the risk of AD. We therefore examined the associations with AD of the *DBH* -1021T allele and of the above interactions in the Epistasis Project, with 1757 cases of AD and 6294 elderly controls.

Methods: We genotyped eight single nucleotide polymorphisms (SNPs) in the three genes, *DBH*, *IL1A* and *IL6*. We used logistic regression models and synergy factor analysis to examine potential interactions and associations with AD.

Results: We found that the presence of the -1021T allele was associated with AD: odds ratio = 1.2 (95% confidence interval: 1.06-1.4, $p = 0.005$). This association was nearly restricted to men < 75 years old: odds ratio = 2.2 (1.4-3.3, 0.0004). We also found an interaction between the presence of *DBH* -1021T and the -889TT genotype (rs1800587) of *IL1A*: synergy factor = 1.9 (1.2-3.1, 0.005). All these results were consistent between North Europe and North Spain.

Conclusions: Extensive, previous evidence (reviewed here) indicates an important role for noradrenaline in the control of inflammation in the brain. Thus, the -1021T allele with presumed low activity may be associated with misregulation of inflammation, which could contribute to the onset of AD. We suggest that such misregulation is the predominant mechanism of the association we report here.

Background

Noradrenergic neurones in Alzheimer's disease

The loss of noradrenergic neurones of the locus coeruleus is a striking feature of sporadic Alzheimer's disease (AD). A gradual, moderate loss is found with ageing in healthy people [1-3], but a more dramatic loss is seen in

AD. A meta-analysis [4] showed similarly high losses of noradrenergic neurones (24 studies) as of cholinergic neurones (33 studies), with losses four times greater than those of dopaminergic cells in AD. Noradrenergic neurones project from the brainstem to innervate wide areas of the forebrain [5]. Levels of noradrenaline (NA, norepinephrine) in target regions have also sometimes been reported lowered in ageing [6,7], e.g. in the hippocampus and hypothalamus. They have generally been found to be further reduced in AD [8-13], e.g. in the hippocampus, hypothalamus, caudate nucleus, putamen and neocortex,

* Correspondence: combarro@unican.es

¹Neurology Service and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Marqués de Valdecilla University Hospital (University of Cantabria), 39008 Santander, Spain
Full list of author information is available at the end of the article

although not in one small study [14]. Both the loss of noradrenergic neurones [15] and that of NA in target regions [8,13,16] have been correlated with the severity of the disease. Changes in the noradrenergic system in AD are reviewed in Hermann et al 2004 [17].

Dopamine β -hydroxylase -1021C/T

Dopamine β -hydroxylase (DBH) catalyses the conversion of dopamine to NA. Its activity is also reduced in post-mortem hippocampus and neocortex in AD [18,19], without correlating with the loss of noradrenergic neurones [19]. Variation in DBH activity both in serum and in CSF has been reported to be over 80% heritable [20]. The single nucleotide polymorphism (SNP), -1021C/T (rs1611115), has been identified as the main predictor of DBH activity in plasma [21,22]. It is responsible for ~30% to ~50% of the considerable variation in such activity between people, as replicated in several different populations [21,23-27]. The -1021T allele contributes to greatly lowered DBH activity through codominant inheritance [21]. In view therefore of the chronic inflammation seen in the AD brain [28,29] and of the anti-inflammatory role of NA [30], Mateo et al 2006 [31] investigated interactions between the -1021T allele and SNPs of the regulatory regions of the pro-inflammatory cytokine genes, *IL1A* and *IL6*. They reported interactions between *DBH* -1021TT and both *IL1A* -889T (rs1800587) and *IL6* -174GG (rs1800795). In the Epistasis Project, we recently confirmed [32] reported interactions between the inflammation-related cytokine genes, *IL6* and *IL10*, that contribute to the development of AD. We therefore now decided also to examine the interactions between *DBH* and both *IL1A* and *IL6* in the Epistasis Project, with 1757 cases of AD and 6294 controls. In view of the age and sex differences that have been reported in brain inflammation in the elderly [33], and of the relevant influence of sex steroids [34], we also examined possible interactions of *DBH* with age and sex. We found an association of the low-activity *DBH* -1021T allele with the risk of AD.

Methods

Study population

The Epistasis Project aims primarily to replicate interactions that have been reported to affect the risk of AD. Sample-sets were drawn from narrow geographical regions with relatively homogeneous, Caucasian populations, by seven AD research groups: Bonn, Bristol, Nottingham, OPTIMA (Oxford), Oviedo, Rotterdam and Santander. Sample characteristics by geographical region are given in Additional file 1: Table S1. All AD cases were diagnosed "definite" or "probable" by CERAD or NINCDS-ADRDA criteria. AD cases were sporadic, i.e. possible autosomal dominant cases were excluded, based on family history.

The median ages (interquartile ranges) of AD cases were 79.0 (73.0-85.2) and of controls were 76.9 (71.3-83.0). Fuller details of our sample-sets are given elsewhere [32]. Ethical approval was obtained by each of the participating groups (Additional file 1: Table S2).

Genotyping

Blood samples were taken after written informed consent had been obtained from the subjects or their representatives. Genotyping for the six centres other than Rotterdam (below) was performed at the Wellcome Trust Sanger Institute, using the iPLEX Gold assay (Sequenom Inc.). Whole genome amplified DNA was used for 82% of samples; genomic DNA was used for the 18% of samples that were not suitable for whole genome amplification. A Sequenom iPLEX, designed for quality control purposes, was used to assess genotype concordance between genomic and whole genome amplified DNA for 168 individuals. Assays for all SNPs were designed using the eXTEND suite and MassARRAY Assay Design software version 3.1 (Sequenom Inc.). Samples were amplified in multiplexed PCR reactions before allele specific extension. Allelic discrimination was obtained by analysis with a MassARRAY Analyzer Compact mass spectrometer. Genotypes were automatically assigned and manually confirmed using MassArray TyperAnalyzer software version 4.0 (Sequenom Inc.). Gender markers were included in all iPLEX assays as a quality control metric for confirmation of plate/sample identity. Genotyping of *DBH* intron 10 A/G (rs1611131) and *IL6* intron 2 A/G (rs2069837) was carried out using KASPar technology by KBioscience <http://www.kbioscience.co.uk>. No SNPs were imputed.

Genotyping in the Rotterdam cohort was done on Version 3 Illumina-Infinium-II HumanHap550 SNP array (Illumina, San Diego, USA) and additionally, SNPs were imputed using MACH software <http://www.sph.umich.edu/csg/abecasis/MACH/> with HapMap CEU Release 22 as a reference [35]. The reliability of imputation was estimated for each imputed SNP with the ratio of expected and observed dosage variance (O/E ratio). Only samples with high-quality extracted DNA were genotyped; 5974 were available with good quality genotyping data; 5502 of these had reliable phenotypes. For this study, *DBH* exon 3 Ala197Thr (rs5320), *IL1A* exon 5 Ala114Ser (rs17561) and *IL6* intron 2 A/G (rs2069837) were genotyped, and the other SNPs (Table 1) were imputed.

Statistical analysis

We assessed associations with logistic regression models, controlling for age, gender, study centre and the $\epsilon 4$ allele of apolipoprotein E (*APOE* $\epsilon 4$), using R Version 2.10.1 (R Foundation for Statistical Computing, Vienna, Austria). The adjusted synergy factors [36] were derived from the

Table 1 Studied SNPs

Gene	SNP		Minor allele frequency in controls			Linkage disequilibrium in controls				
			North Europe	North Spain	Difference (<i>p</i>)	With	North Europe		North Spain	
							<i>D'</i>	<i>r</i> ²	<i>D'</i>	<i>r</i> ²
<i>DBH</i>	rs1611115	-1021C/T	20.7% (T)	19.7% (T)	0.47	rs5320	0.994	0.015	0.994	0.017
	rs 5320	Exon 3 Ala197Thr	5.3% (A, Thr)	6.0% (A, Thr)	0.38	rs1611131	0.257	0.002	0.393	0.003
	rs1611131	Intron 10 A/G	29.4% (G)	24.5% (G)	0.002	rs1611115	0.295	0.055	0.250	0.047
<i>IL1A</i>	rs1800587	-889C/T	29.2% (T)	25.4% (T)	0.01	rs17561	0.999	0.994	0.989	0.971
	rs17561	Exon 5 Ala114Ser	29.2% (T, Ser)	25.6% (T, Ser)	0.02	rs3783550	0.997	0.185	0.999	0.145
	rs3783550	Intron 6 A/C	31.2% (C)	29.8% (C)	0.39	rs1800587	0.994	0.185	0.999	0.144
<i>IL6</i>	rs1800795	-174G/C	41.1% (C)	32.8% (C)	4 × 10⁻⁷	rs2069837	0.999	0.055	0.998	0.049
	rs2069837	Intron 2 A/G	7.3% (G)	9.3% (G)	0.03					

SNP = single nucleotide polymorphism, *DBH* = dopamine β-hydroxylase, *IL1A* = interleukin-1α, *IL6* = interleukin-6, *D'* = ratio of observed linkage disequilibrium to maximum possible linkage disequilibrium, *r*² = correlation coefficient.

Results in bold are significant at *p* < 0.05.

interaction terms in those models. Since both -1021TT and -1021TC are associated with reduced plasma *DBH* activity, although the former more so than the latter, we combined the two genotypes in all analyses, i.e. using a model that assumes that the -1021T allele is dominant. For reasons of power, it is usual to use minor-allele-dominant models in interaction analyses, even where a codominant model might produce a better fit. This is the almost invariable practice with the *APOEε4* allele.

Heterogeneity among centres was controlled thus. We first fitted a model including random effect terms by centre, which accounts for correlated (clustered) observations within populations while avoiding estimating extra parameters in the regression models. We then fitted centre as a fixed effect term with six contrasts. We compared the goodness of fit of both approaches using Akaike's Information Criterion, which penalises the model's likelihood by a function of the number of parameters in the model. We found that the model with fixed effect terms by centre was preferable and used it to control for different frequencies between populations. Overdispersion was controlled by fitting generalized linear models with a quasi-binomial family with logit link.

Where the overall synergy factor was significant at *p* < 0.05, the seven individual centres and the two geographical regions, North Europe and North Spain, were also examined. In view of the genetic differences found between North and South Europe in previous studies [37-39] and in the Epistasis Project (Table 1, Additional file 1: Table S1, and [40]), we included separate analyses for North Europe and North Spain. North Europe here comprises Bonn, Bristol, Nottingham, Oxford and Rotterdam; North Spain comprises Oviedo and Santander.

Power calculations were based on the observed synergy factor values. A Cox proportional hazards model, with a frailty term to account for centre differences, controlling also for sex and *APOE4*, was fitted to see whether the *DBH* -1021T allele was associated with the onset age of AD, after confirming the assumption of proportional hazards. Comparisons of allelic frequencies between North Spain and North Europe were by Fisher's exact test. Linkage disequilibrium data were estimated using the R genetics library <http://cran.r-project.org/web/packages/genetics/index.html>. All tests of significance and power calculations were two-sided.

Results

The data

Table 1 shows the allelic frequencies and patterns of linkage disequilibrium of the eight studied SNPs in controls. There were differences between North Europe and North Spain in allelic frequencies of five SNPs. *IL1A* -889C/T and exon 5 Ala114Ser were in almost 100% linkage disequilibrium. Genotype distributions of the eight SNPs in AD and controls from each of the seven centres are shown in Additional file 1: Table S3; allelic frequencies by country are given in Additional file 1: Table S4. Hardy-Weinberg analysis was performed for both cases and controls, both in the Rotterdam samples and in the samples from the other six centres, which were genotyped by the Sanger Institute. In three of these 32 analyses, the samples were not in Hardy-Weinberg equilibrium, compared with two as would be expected by chance. Those three sample-sets were all AD cases from the six centres: *IL1A* -889C/T (*p* = 0.03) and intron 6 A/C (*p* = 0.004), and *IL6* -174G/C (*p* = 0.02). Since another

SNP, Arg535Cys in exon 11 of *DBH* (rs6271), has also been reported to influence plasma DBH activity [23,24], although much less so than -1021C/T, we performed preliminary analysis of that SNP on data from six centres, i.e. excluding Rotterdam.

Associations of *DBH* -1021TT+TC with AD

DBH -1021TT+TC versus CC was associated with AD overall: odds ratio = 1.2 (95% confidence interval: 1.06-1.4, $p = 0.005$). There were interactions with sex and age (Table 2). The interaction with sex was significant overall and in North Europe, while that with age was significant overall and in North Spain. In view of those interactions, we stratified our analyses by age and by sex. Those stratified analyses established that the observed association of *DBH* -1021TT+TC with AD in the population was due to an association nearly restricted to men < 75 years old: odds ratio = 2.2 (1.4-3.3, 0.0004) (Table 3). Similar results were obtained in North Europe and North Spain (Table 4). The *DBH* -1021T allele was not associated with onset age of AD.

Interactions with *IL1A* and *IL6*

We found an interaction between *DBH* -1021TT+TC and *IL1A* -889TT (Table 5): synergy factor = 1.9 (1.2-3.1, 0.005). This interaction was consistent between North Europe and North Spain. We also found a possible interaction between *DBH* -1021TT+TC and *IL6* -174GG (Table 5), but only in North Europe: synergy factor = 1.5 (1.07-2.0, 0.02) (Table 5). We also analysed the results for *DBH* -1021TT+TC and *IL1A* -889TT when stratified by each other (Table 6). Those analyses showed that each risk factor was only associated with AD in the presence of the other factor.

Other *DBH* SNPs: exon 3 Ala197Thr (rs5320), intron 10 A/G (rs1611131) and exon 11 Arg535Cys (rs6271)

There were no main effects of any of these SNPs. The overall odds ratio for 197Ala homozygotes (versus

Table 3 Odds ratios of AD for *DBH* -1021TT+TC vs CC, stratified by sex and by age

Subset	Adjusted* odds ratios of AD (95% CI, p)
Men	1.6 (1.2-2.0, 0.0002)
Women	1.05 (0.9-1.2, 0.60)
All < 75 years	1.6 (1.2-2.2, 0.001)
All > 75 years	1.06 (0.9-1.3, 0.47)
Men < 75 years	2.2 (1.4-3.3, 0.0004)
Men > 75 years	1.35 (0.98-1.8, 0.06)
Women < 75 years	1.3 (0.9-1.9, 0.24)
Women > 75 years	0.95 (0.8-1.2, 0.66)

AD = Alzheimer's disease, *DBH* = dopamine β -hydroxylase, CI = confidence interval.

* All analyses controlled for centre, age, sex and genotype of apolipoprotein E ϵ 4.

Results in bold are significant at $p < 0.05$.

carriers of one or two copies of Thr) was 1.01 (0.8-1.25, 0.9) and for intron 10 AA (versus AG+GG) was 0.97 (0.85-1.1, 0.7). However, the interaction of 197Ala homozygotes with sex was slightly stronger than that of -1021TT+TC, but only in Northern Europeans: synergy factor = 2.3 (1.4-3.9, 0.001). The only apparently significant result for intron 10 AA was an interaction with age, only in Northern Spanish, very similar to that of -1021TT+TC: synergy factor = 2.1 (1.1-3.95, 0.025). The only apparently significant result in the preliminary analysis of Arg535Cys was probably due to chance (data not shown).

Discussion

Interpretation of results

We have shown a clear association between the presence of the *DBH* -1021T allele and AD (Table 4): odds ratio for -1021TT+TC versus CC = 1.2 (1.06-1.4, 0.005), controlling for centre, age, sex and *APOE* ϵ 4 genotype. This association was nearly restricted to men < 75 years old: 2.2 (1.4-3.3, 0.0004). The interactions with sex and age were both significant ($p = 0.01$ and 0.03, respectively,

Table 2 Interactions of *DBH* -1021TT+TC versus CC with sex and age in AD risk

Interaction	Dataset	Numbers		Power*	Adjusted [†] synergy factor (95% CI, p)
		Controls	AD		
With sex	All	6201	1611	88%	1.4 (1.1-1.9, 0.01)
	North Europe	5708	1109	78%	1.6 (1.1-2.1, 0.006)
	North Spain	493	502	32%	1.3 (0.7-2.5, 0.4)
With age (\pm 75 years)	All	6200	1611	85%	1.4 (1.04-1.9, 0.03)
	North Europe	5708	1109	73%	1.3 (0.9-1.8, 0.2)
	North Spain	492	502	32%	2.1 (1.1-3.9, 0.02)

DBH = dopamine β -hydroxylase, AD = Alzheimer's disease, CI = confidence interval.

* power to detect a synergy factor of 1.4, as in the overall dataset, at $p < 0.05$.

[†] All analyses controlled for centre, age, sex and genotype of apolipoprotein E ϵ 4.

Results in bold are significant at $p < 0.05$.

Table 4 Odds ratios of AD for *DBH* -1021TT+TC vs CC in certain subsets

Subset	Adjusted* odds ratios of AD (95% CI, p)		
	All	North Europe	North Spain
All	1.2 (1.06-1.4, 0.005)	1.2 (1.05-1.4, 0.01)	1.3 (0.97-1.7, 0.08)
Men	1.6 (1.2-2.0, 0.0002)	1.7 (1.3-2.2, 0.0002)	1.5 (0.9-2.55, 0.12)
All < 75 years	1.6 (1.2-2.2, 0.001)	1.55 (1.1-2.2, 0.02)	1.8 (1.04-3.0, 0.03)
Men < 75 years	2.2 (1.4-3.3, 0.0004)	2.2 (1.3-3.8, 0.002)	1.9 (0.8-4.4, 0.12)

AD = Alzheimer's disease, *DBH* = dopamine β-hydroxylase, CI = confidence interval.

* All analyses controlled for centre, age, sex and genotype of apolipoprotein E ε4.

Results in bold are significant at $p < 0.05$.

Table 2). Table 3 shows that the effect of age was consistent between men and women and the effect of gender was consistent between the two age groups. All these results were consistent between North Europe and North Spain (Tables 2 & 4). We therefore believe these associations to be real. However, large numbers will be needed to replicate these interactions (see the power estimates in Tables 2 & 5).

We also found a probable interaction between the presence of *DBH* -1021T and *IL1A* -889TT (Table 5), thus partially replicating Mateo et al 2006 [31], who reported an interaction between *DBH* -1021TT and *IL1A* -889T. The synergy factors were consistent between North Europe and North Spain (Table 5). Also, each risk factor, i.e. *DBH* -1021T and *IL1A* -889TT, was only associated with AD risk in the presence of the interacting factor (Table 6), thus indicating epistasis. However, although the results were consistent in the three largest sample-sets, Rotterdam, Santander and OPTIMA, models for the smaller sample-sets proved unreliable. Thus we can only describe this interaction as probable, not definite. The *IL1A* -889TT genotype has been found to increase transcriptional activity in assays of promoter function [41,42]. Meta-analyses [43-45] have shown heterogeneity between studies, but a possible, weak association of the -889T allele with AD: odds

ratio = 1.07 (0.99-1.16) (23 Sept 2010, 29 sample-sets: <http://www.alzgene.org/>).

We also found a possible interaction between *DBH* -1021T and *IL6* -174GG, partially replicating that between *DBH* -1021TT and *IL6* -174GG reported by Mateo et al [31]. However, in this case the interaction was only seen in North Europe and the results were inconsistent between the two European regions (Table 5) and between the seven centres. Thus, this apparent interaction may not be real. The only apparently significant results for the other two *DBH* SNPs studied in our full dataset, exon 3 Ala197Thr (rs5320) and intron 10 A/G (rs1611131), were somewhat inconsistent, precluding any firm conclusions.

The -1021T allele has consistently been associated with strikingly reduced plasma *DBH* activity [21,23-27]. The allele partially disrupts consensus transcriptional motifs for *n-MYC* and *MEF-2* [26]. When *DBH* promoter/reporters were cotransfected with *n-MYC* or *MEF-2*, the allele affected the response [26]. The allele is thus functional and, although we cannot assume that it has the same effect in the brain as in the plasma, we may plausibly speculate that it does also have some influence on *DBH* activity in the brain. *DBH* catalyses the conversion of dopamine to NA. The -1021C/T SNP may therefore affect levels of both catecholamines. However, although reduced levels of NA are seen in AD brain

Table 5 Interactions of *DBH* -1021TT+TC vs CC with variants of *IL1A* and *IL6* in AD risk

Interaction with	Dataset	Numbers		Power*	Adjusted [†] synergy factor (95% CI, p)
		Controls	AD		
<i>IL1A</i> -889TT vs TC+CC	All	6137	1535	93%	1.9 (1.2-3.1, 0.005)
	North Europe	5678	1078	87%	1.7 (1.02-2.8, 0.04)
	North Spain	459	457	32%	3.4 (0.9-12.3, 0.07)
<i>IL6</i> -174GG vs GC+CC	All	6161	1565	95%	1.3 (0.98-1.7, 0.07)
	North Europe	5692	1084	88%	1.5 (1.07-2.0, 0.02)
	North Spain	469	481	44%	0.94 (0.5-1.7, 0.85)

The first column indicates the models used to represent the SNPs, *IL1A* -889T/C and *IL6* -174G/C, in the analyses of interactions with *DBH* -1021C/T.

AD = Alzheimer's disease, *DBH* = dopamine β-hydroxylase, CI = confidence interval.

* Power to detect a synergy factor of 1.9 (first interaction) or 1.5 (second interaction) at $p < 0.05$.

[†] All analyses controlled for centre, age, sex and genotype of apolipoprotein E ε4.

Results in bold are significant at $p < 0.05$.

Table 6 Odds ratios of AD for the *DBH* and *IL1A* variants*, when stratified by each other

Odds ratio of AD for:-	In the subset:-	Numbers		Adjusted [†] odds ratio of AD (95% CI, <i>p</i>)
		Controls	AD	
<i>DBH</i> -1021TT+TC vs CC	<i>IL1A</i> -889TC+CC	CC: 3546	CC: 862	1.1 (0.99-1.3, 0.07)
		TT+TC: 2077	TT+TC: 516	
	<i>IL1A</i> -889TT	CC: 340	CC: 87	2.25 (1.4-3.6, 0.0008)
		TT+TC: 174	TT+TC: 70	
<i>IL1A</i> -889TT vs TC+CC	<i>DBH</i> -1021CC	TC+CC: 3546	TC+CC: 862	0.95 (0.7-1.3, 0.76)
		TT: 340	TT: 87	
	<i>DBH</i> -1021TT+TC	TC+CC: 2077	TC+CC: 516	1.8 (1.3-2.6, 0.0009)
		TT: 174	TT: 70	

AD = Alzheimer's disease, *DBH* = dopamine β-hydroxylase, *IL1A* = interleukin-1α, CI = confidence interval.

* *DBH* -1021TT+TC vs CC and *IL1A* -889TT vs TC+CC.

† All analyses controlled for centre, age, sex and genotype of apolipoprotein E ε4.

Results in bold are significant at *p* < 0.05.

[8-13], raised levels of dopamine have generally not been found [8,12,13]. We will therefore base the discussion below on the hypothesis that the association of the -1021T allele with AD risk is mainly due to an effect on NA levels in the brain.

The control of inflammation in the brain

One likely result of changed *DBH* activity is misregulation of inflammation in the brain. The mechanisms that control inflammation in the brain differ from those in the periphery; an important part of the former control system is the noradrenergic network (reviewed in [30]). The anti-inflammatory role of NA has been shown in cultured cells and rodent brains (reviewed in [30]). Raised levels of NA reduced activation of astrocytes [46] and microglia [47-49], and lowered expression of pro-inflammatory cytokines [47-50] and chemokines [50]. Noradrenergic depletion increased production of pro-inflammatory cytokines [51] and chemokines [52], and activation of astrocytes [53] and microglia [51], and impaired microglial phagocytosis of β-amyloid [50]. Astrocytes are considered major targets of noradrenaline in the brain (reviewed in [54,55]), through their β₂-adrenoceptors [46,54], which activate the cyclic AMP pathway [54,56], which may lead to the activation of peroxisome proliferator-activated receptors (PPARs) [56-58]. These receptors down-regulate expression of pro-inflammatory genes (PPARγ: [59]; PPARδ: [60]). The importance of the cyclic AMP pathway in AD was underlined by the recent identification of the cyclic AMP-response element-binding protein as the transcription factor of most relevance to networks of AD-related genes [61]. The inhibition of the pro-inflammatory transcription factor, nuclear factor κB, by its endogenous inhibitor, IκB, may also mediate the anti-inflammatory effects of NA [62-64]. However, the anti-inflammatory role of NA remains controversial [53] and it may even have pro-inflammatory actions in certain

conditions [65-67]. Nevertheless, the predominant evidence suggests a mainly anti-inflammatory, regulatory role of NA in the brain. This role is weakened in ageing [1-3] and seriously disrupted in AD [4]. Thus, elderly non-demented carriers of the *DBH* -1021T allele with presumed low activity may be more vulnerable to low-grade inflammation in the brain. This effect has been reported to be stronger in elderly men < 80 years old [33], consistent with our results.

Other potential mechanisms

In cell cultures and rodent brains, brain-derived neurotrophic factor (BDNF) has been reported: to be induced by NA in astrocytes and neurones [68-71]; to exert certain neuroprotective actions (reviewed in [72]); and to promote synaptic plasticity and contribute to learning and memory (reviewed in [73]). BDNF levels have been found to be decreased in the postmortem hippocampus and neocortex [74-76] in AD. A large recent meta-analysis of the *BDNF* Val66Met polymorphism [77] found that the Met allele was associated with AD in women, but not men.

Noradrenergic neurones also produce and secrete other neuromodulators and neurotrophins (reviewed in [78]). These neurones also have roles in glial energy metabolism [54,55] and the maintenance of the microvasculature [79,80] and of the blood-brain barrier [81]. NA has actions against oxidative stress [57,82,83] and against excitotoxicity [84,85]. Downstream of NA, the cyclic AMP pathway has neuroprotective and antioxidant actions in neuronal cultures [86,87]. NA protects against the neurotoxicity of β-amyloid (reviewed in [88]). However, potentially pathogenic contributions of NA to AD have also been reported [65,67,89].

Conclusions

Our results support an association of the functional *DBH* -1021T allele with increased risk of AD in men

< 75 years. Any of the above neuroprotective effects of NA (reviewed in [90]) may influence that risk and that association. However, there is considerable evidence for the role of NA in the control of inflammation in the brain (reviewed in [30]). In view therefore also of the likely interaction between *DBH* and the pro-inflammatory gene, *IL1A*, we suggest that the predominant, although not sole, mechanism of the above association with AD is misregulation of inflammation in the brain. There is substantial evidence that inflammation is an early, pre-clinical factor in the development of AD (reviewed in [91]). We have previously proposed [32] that inflammation is not only a reaction to the pathology of AD, but contributes to its onset. Our present results support that view.

Additional material

Additional file 1: Combarros et al 2010: The dopamine β -hydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis Project.

Abbreviations

AD: Alzheimer's disease; *APOE* ϵ 4: apolipoprotein E ϵ 4; CERAD: Consortium to Establish a Registry for Alzheimer's Disease; CI: confidence interval; CSF: cerebrospinal fluid; DBH: dopamine β -hydroxylase; *DBH*: the gene for DBH; *IL1A*: the gene for interleukin-1 α ; *IL6*: the gene for interleukin-6; NINCDS-ADRDA: National Institute of Neurological, Communicative Diseases and Stroke-Alzheimer's Disease and Related Diseases Association; OPTIMA: the Oxford Project to Investigate Memory and Ageing; SNP: single nucleotide polymorphism.

Acknowledgements

We are most grateful to the Moulton Charitable Foundation for a grant to fund the Epistasis Project, to all those who have provided support for the individual clinical studies and to the Alzheimer's Research Trust and the Thomas Willis Oxford Brain Collection for tissue for DNA extraction. GW was partly funded by the NIHR Biomedical Research Centre Programme, Oxford. UCL Institute of Child Health receives funding from the Department of Health's NIHR Biomedical Research Centres funding scheme. The Centre for Paediatric Epidemiology and Biostatistics also benefits from funding support from the Medical Research Council in its capacity as the MRC Centre of Epidemiology for Child Health (G0400546). The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE1 and 2), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The generation and management of GWAS genotype data for the Rotterdam Study is supported by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012).

Author details

¹Neurology Service and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Marqués de Valdecilla University Hospital (University of Cantabria), 39008 Santander, Spain. ²Oxford Project to Investigate Memory and Ageing (OPTIMA), University Department of Physiology, Anatomy and Genetics, South Parks Road, Oxford OX1 3QX, UK. ³The Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK. ⁴Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, 30 Guilford Street, London WC1N 1EH, UK. ⁵School of Molecular Medical Sciences, Institute of Genetics, University of

Nottingham, Queens Medical Centre, Nottingham NG7 2UH, UK. ⁶Nuffield Department of Medicine, University of Oxford, Level 4, John Radcliffe Hospital, Oxford OX3 9DU, UK. ⁷Dementia Research Group, Institute of Clinical Neurosciences, University of Bristol, Frenchay Hospital, Frenchay Bristol, BS16 1LE, UK. ⁸Genética Molecular, Hospital Central de Asturias, Oviedo, Spain. ⁹Department of Psychiatry, University of Bonn, Bonn, Germany. ¹⁰Royal Derby Hospital, Uttoxeter Road, Derby DE22 3NE, UK. ¹¹OPTIMA, Nuffield Department of Medicine, University of Oxford, Level 4, John Radcliffe Hospital, Oxford OX3 9DU, UK. ¹²Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands. ¹³Department of Psychiatry, Donders Institute for Brain, Cognition and Behavior & Department of Human Genetics, Radboud University Nijmegen, Medical Centre, P.O. Box 9101, HP 966, Nijmegen 6500 HB, The Netherlands. ¹⁴Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.

Authors' contributions

All authors contributed to the design of the study. In addition, ADS and DJL set up the Epistasis Project, with the help of the other authors. ADS and DJL decided on the strategy of the Epistasis Project, with the help of CMvD, OC, KM, PK, RH, MC-B, DRW and EC. ADS, DJL, CMvD, OC, KM, PK, RH, MC-B, DRW and EC chose the genetic interactions to study. OC and IM produced the hypothesis for this study. KM and OB gave extensive advice on the choice of SNPs to study. DJL made the final selection of polymorphisms. HK, RB, KM, DRW, EC and IM provided DNA for genotyping. DRW gave technical advice throughout. RG and NH were responsible for the genotyping of 6 sample-sets. AA-V was responsible for the Rotterdam genotyping. MC-B and DJL decided on the analytical approach. MC-B and AO advised on statistics. DJL, MGL, MC-B and AO performed the analyses. DJL drafted the manuscript. OC submitted the manuscript and is responsible for correspondence. All authors read the manuscript, studied it critically for its intellectual content and approved the final draft.

Competing interests

The authors declare that they have no competing interests.

Received: 4 June 2010 Accepted: 11 November 2010

Published: 11 November 2010

References

1. Brody H: **An examination of cerebral cortex and brainstem aging.** In *Neurobiology of Aging*. Edited by: Terry RD, Gershon S: Raven Press, New York; 1976.
2. Mann DMA, Yates PO, Hawkes J: **The pathology of the human locus ceruleus.** *Clin Neuropathol* 1983, **2**:1-7.
3. Tomlinson BE, Irving D, Blessed G: **Cell loss in the locus coeruleus in senile dementia of Alzheimer type.** *J Neurol Sci* 1981, **49**:419-428.
4. Lyness SA, Zarow C, Chui HC: **Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis.** *Neurobiol Aging* 2003, **24**:1-23.
5. Sara SJ: **The locus coeruleus and noradrenergic modulation of cognition.** *Nat Rev Neurosci* 2009, **10**(3):211-223.
6. Carlsson A, Adolfsson R, Aquilonius SM, Gottfries CG, Orelund L, Svennerholm L, Winblad B: **Biogenic amines in human brain in normal aging, senile dementia, and chronic alcoholism.** *Adv Biochem Psychopharmacol* 1980, **23**:295-304.
7. Winblad B, Hardy J, Bäckman L, Nilsson LG: **Memory function and brain biochemistry in normal aging and in senile dementia.** *Ann N Y Acad Sci* 1985, **444**:255-268.
8. Adolfsson R, Gottfries CG, Roos BE, Winblad B: **Changes in the brain catecholamines in patients with dementia of Alzheimer type.** *Br J Psychiatry* 1979, **135**:216-223.
9. Francis PT, Palmer AM, Sims NR, Bowen DM, Davison AN, Esiri MM, Neary D, Snowden JS, Wilcock GK: **Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment.** *N Engl J Med* 1985, **313**(1):7-11.
10. Gottfries CG, Adolfsson R, Aquilonius SM, Carlsson A, Eckernas SA, Nordberg A, Orelund L, Svennerholm L, Wiberg A, Winblad B: **Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT).** *Neurobiol Aging* 1983, **4**(4):261-271.

11. Hoogendijk WJG, Feenstra MGP, Botterblom MHA, Gilhuis J, Sommer IEC, Kamphorst W, Eikelenboom P, Swaab DF: **Increased activity of surviving locus ceruleus neurons in Alzheimer's disease.** *Ann Neurol* 1999, **45**:82-91.
12. Palmer AM, Wilcock GK, Esiri MM, Francis PT, Bowen DM: **Monoaminergic innervation of the frontal and temporal lobes in Alzheimer's disease.** *Brain Res* 1987, **401**(2):231-238.
13. Reinikainen KJ, Soininen H, Riekkinen PJ: **Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy.** *J Neurosci Res* 1990, **27**:576-586.
14. D'Amato RJ, Zweig RM, Whitehouse PJ, Wenk GL, Singer HS, Mayeux R, Price DL, Snyder SH: **Aminergic systems in Alzheimer's disease and Parkinson's disease.** *Ann Neurol* 1987, **22**:229-236.
15. Bondareff W, Mountjoy CQ, Roth M, Rossor MN, Iversen LL, Reynolds GP, Hauser DL: **Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer's disease.** *Alzheimer Dis Assoc Disord* 1987, **1**:256-262.
16. Matthews KL, Chen CP, Esiri MM, Keene J, Minger SL, Francis PT: **Noradrenergic changes, aggressive behavior, and cognition in patients with dementia.** *Biol Psychiatry* 2002, **51**(5):407-416.
17. Herrmann N, Lanctôt KL, Khan LR: **The role of norepinephrine in the behavioral and psychological symptoms of dementia.** *J Neuropsychiatry Clin Neurosci* 2004, **16**(3):261-276.
18. Cross AJ, Crow TJ, Perry EK, Perry RH, Blessed G, Tomlinson BE: **Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease.** *British medical journal (Clinical research ed)* 1981, **282**(6258):93-94.
19. Perry EK, Tomlinson BE, Blessed G, Perry RH, Cross AJ, Crow TJ: **Neuropathological and biochemical observations on the noradrenergic system in Alzheimer's disease.** *J Neurol Sci* 1981, **51**:279-287.
20. Oxenstierna G, Edman G, Iselius L, Orelund L, Ross SB, Sedvall G: **Concentrations of monoamine metabolites in the cerebrospinal fluid of twins and unrelated individuals—a genetic study.** *J Psychiatr Res* 1986, **20**(1):19-29.
21. Zabetian CP, Anderson GM, Buxbaum SG, Elston RC, Ichinose H, Nagatsu T, Kim KS, Kim CH, Malison RT, Geleterter J, et al: **A quantitative-trait analysis of human plasma dopamine β-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus.** *Am J Hum Genet* 2001, **68**:515-522.
22. Zabetian CP, Buxbaum SG, Elston RC, Köhnke MD, Anderson GM, Geleterter J, Cubells JF: **The structure of linkage disequilibrium at the DBH locus strongly influences the magnitude of association between diallelic markers and plasma dopamine β-hydroxylase activity.** *Am J Hum Genet* 2003, **72**:1389-1400.
23. Tang YL, Epstein MP, Anderson GM, Zabetian CP, Cubells JF: **Genotypic and haplotypic associations of the DBH gene with plasma dopamine beta-hydroxylase activity in African Americans.** *Eur J Hum Genet* 2007, **15**(8):878-883.
24. Tang Y, Anderson GM, Zabetian CP, Köhnke MD, Cubells JF: **Haplotype-controlled analysis of the association of a non-synonymous single nucleotide polymorphism at DBH (+ 1603C → T) with plasma dopamine beta-hydroxylase activity.** *Am J Med Genet B Neuropsychiatr Genet* 2005, **139B**(1):88-90.
25. Köhnke MD, Zabetian CP, Anderson GM, Kolb W, Gaertner I, Buchkremer G, Vonthein R, Schick S, Lutz U, Köhnke AM, et al: **A genotype-controlled analysis of plasma dopamine beta-hydroxylase in healthy and alcoholic subjects: evidence for alcohol-related differences in noradrenergic function.** *Biol Psychiatry* 2002, **52**(12):1151-1158.
26. Chen Y, Wen G, Rao F, Zhang K, Wang L, Rodriguez-Flores JL, Sanchez AP, Mahata M, Taupenot L, Sun P, et al: **Human dopamine beta-hydroxylase (DBH) regulatory polymorphism that influences enzymatic activity, autonomic function, and blood pressure.** *J Hypertens* 2010, **28**:76-86.
27. Bhaduri N, Mukhopadhyay K: **Correlation of plasma dopamine β-hydroxylase activity with polymorphisms in DBH gene: a study on Eastern Indian population.** *Cell Mol Neurobiol* 2008, **28**(3):343-350.
28. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, et al: **Inflammation and Alzheimer's disease.** *Neurobiol Aging* 2000, **21**:383-421.
29. Rogers J, Webster S, Lue L-F, Brachova L, Civin WH, Emmerling M, Shivers B, Walker D, McGeer P: **Inflammation and Alzheimer's disease pathogenesis.** *Neurobiol Aging* 1996, **17**:681-686.
30. Feinstein DL, Heneka MT, Gavriluk V, Dello Russo C, Weinberg G, Galea E: **Noradrenergic regulation of inflammatory gene expression in brain.** *Neurochem Int* 2002, **41**:357-365.
31. Mateo I, Infante J, Rodríguez E, Berciano J, Combarros O, Llorca J: **Interaction between dopamine β-hydroxylase and interleukin genes increases Alzheimer's disease risk.** *J Neurol Neurosurg Psychiatry* 2006, **77**:278-279.
32. Combarros O, van Duijn CM, Hammond N, Belbin O, Arias-Vásquez A, Cortina-Borja M, Lehmann MG, Aulchenko YS, Schuur M, Kölsch H, et al: **Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease.** *J Neuroinflammation* 2009, **6**:22.
33. Overmyer M, Helisalmi S, Soininen H, Laakso M, Riekkinen PS, Alafuzoff I: **Reactive microglia in aging and dementia: an immunohistochemical study of postmortem human brain tissue.** *Acta Neuropathol (Berl)* 1999, **97**:383-392.
34. Kipp M, Beyer C: **Impact of sex steroids on neuroinflammatory processes and experimental multiple sclerosis.** *Front Neuroendocrinol* 2009, **30**(2):188-200.
35. Ikram MA, Seshadri S, Bis JC, Fornage M, DeStefano AL, Aulchenko YS, Debette S, Lumley T, Folsom AR, van den Herik EG, et al: **Genomewide association studies of stroke.** *N Engl J Med* 2009, **360**:1718-1728.
36. Cortina-Borja M, Smith AD, Combarros O, Lehmann DJ: **The synergy factor: a statistic to measure interactions in complex diseases.** *BMC Res Notes* 2009, **2**(1):105.
37. Merryweather-Clarke AT, Pointon JJ, Jouanolle AM, Rochette J, Robson KJH: **Geography of HFE C282Y and H63D mutations.** *Genet Test* 2000, **4**:183-198.
38. Lehmann DJ, Cortina-Borja M, Warden DR, Smith AD, Slegers K, Prince JA, van Duijn CM, Kehoe PG: **Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease.** *Am J Epidemiol* 2005, **162**:305-317.
39. Capurso C, Solfrizzi V, D'Introno A, Colacicco AM, Capurso SA, Mastroianni F, Liaci M, Vendemiale G, Capurso A, Panza F: **The cathepsin D gene exon 2 (C224T) polymorphism and sporadic Alzheimer's disease in European populations.** *J Gerontol A Biol Sci Med Sci* 2005, **60**(8):991-996.
40. Lehmann DJ, Schuur M, Warden DR, Hammond N, Belbin O, Kölsch H, Lehmann MG, Wilcock GK, Brown K, Kehoe PG, et al: **Transferrin and HFE genes interact in Alzheimer's disease risk: the Epistasis Project.** *Neurobiol Aging* 2010, Epub ahead of print.
41. Dominici R, Cattaneo M, Malferrari G, Archi D, Mariani C, Grimaldi LME, Biunno I: **Cloning and functional analysis of the allelic polymorphism in the transcription regulatory region of interleukin-1a.** *Immunogenetics* 2002, **54**:82-86.
42. Wei X, Chen X, Fontanilla C, Zhao L, Liang Z, Dodel R, Hampel H, Farlow M, Du Y: **C/T conversion alters interleukin-1A promoter function in a human astrocyte cell line.** *Life Sci* 2007, **80**:1152-1156.
43. Rainero I, Bo M, Ferrero M, Valfrè W, Vaula G, Pinessi L: **Association between the interleukin-1a gene and Alzheimer's disease: a meta-analysis.** *Neurobiol Aging* 2004, **25**:1293-1298.
44. Combarros O, Llorca J, Sánchez-Guerra M, Infante J, Berciano J: **Age-dependent association between interleukin-1A (-889) genetic polymorphism and sporadic Alzheimer's disease. A meta-analysis.** *J Neurol* 2003, **250**:987-989.
45. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE: **Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGenet database.** *Nature Genetics* 2007, **39**:17-23, Accessed on 23 Sept, 2010.
46. Frohman EM, Vayuvegula B, Gupta S, van den Noort S: **Norepinephrine inhibits gamma-interferon-induced major histocompatibility class II (Ia) antigen expression on cultured astrocytes via beta-2-adrenergic signal transduction mechanisms.** *Proc Natl Acad Sci USA* 1988, **85**(4):1292-1296.
47. Dello Russo C, Boullerne AI, Gavriluk V, Feinstein DL: **Inhibition of microglial inflammatory responses by norepinephrine: effects on nitric oxide and interleukin-1beta production.** *J Neuroinflammation* 2004, **1**(1):9.
48. Mori K, Ozaki E, Zhang B, Yang L, Yokoyama A, Takeda I, Maeda N, Sakanaka M, Tanaka J: **Effects of norepinephrine on rat cultured microglial cells that express alpha1, alpha2, beta1 and beta2 adrenergic receptors.** *Neuropharmacology* 2002, **43**(6):1026-1034.
49. O'Sullivan JB, Ryan KM, Curtin NM, Harkin A, Connor TJ: **Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a**

- systemic inflammatory challenge: implications for depression and neurodegeneration. *Int J Neuropsychopharmacol* 2009, **12**(5):687-699.
50. Heneka MT, Nadrigny F, Regen T, Martinez-Hernandez A, Dumitrescu-Ozimek L, Terwel D, Jandanhazi-Kurutz D, Walter J, Kirchhoff F, Hanisch UK, et al: **Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine.** *Proc Natl Acad Sci USA* 2010, **107**(13):6058-6063.
51. Heneka MT, Galea E, Gavriluk V, Dumitrescu-Ozimek L, Daeschner J, O'Banion MK, Weinberg G, Klockgether T, Feinstein DL: **Noradrenergic depletion potentiates β -amyloid-induced cortical inflammation: implications for Alzheimer's disease.** *J Neurosci* 2002, **22**:2434-2442.
52. Jandanhazi-Kurutz D, Kummer MP, Terwel D, Vogel K, Dyrks T, Thiele A, Heneka MT: **Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits.** *Neurochem Int* 2010, **57**(4):375-382.
53. Wenk GL, McGann K, Hauss-Wegrzyniak B, Rosi S: **The toxicity of tumor necrosis factor- α upon cholinergic neurons within the nucleus basalis and the role of norepinephrine in the regulation of inflammation: implications for Alzheimer's disease.** *Neuroscience* 2003, **121**(3):719-729.
54. Laureys G, Clinckers R, Gerlo S, Spooren A, Wilczak N, Kooijman R, Smolders I, Michotte Y, De Keyser J: **Astrocytic beta(2)-adrenergic receptors: From physiology to pathology.** *Prog Neurobiol* 2010.
55. Stone EA, Ariano MA: **Are glial cells targets of the central noradrenergic system? A review of the evidence.** *Brain Res Brain Res Rev* 1989, **14**(4):297-309.
56. Klotz L, Sastre M, Kreutz A, Gavriluk V, Klockgether T, Feinstein DL, Heneka MT: **Noradrenaline induces expression of peroxisome proliferator activated receptor γ (PPAR γ) in murine primary astrocytes and neurons.** *J Neurochem* 2003, **86**:907-916.
57. Madrigal JL, Kalinin S, Richardson JC, Feinstein DL: **Neuroprotective actions of noradrenaline: effects on glutathione synthesis and activation of peroxisome proliferator activated receptor delta.** *J Neurochem* 2007, **103**(5):2092-2101.
58. Michael LF, Lazar MA, Mendelson CR: **Peroxisome proliferator-activated receptor gamma1 expression is induced during cyclic adenosine monophosphate-stimulated differentiation of alveolar type II pneumocytes.** *Endocrinology* 1997, **138**(9):3695-3703.
59. Szanto A, Nagy L: **The many faces of PPARgamma: anti-inflammatory by any means?** *Immunobiology* 2008, **213**(9-10):789-803.
60. Bishop-Bailey D, Bystrom J: **Emerging roles of peroxisome proliferator-activated receptor-beta/delta in inflammation.** *Pharmacol Ther* 2009, **124**(2):141-150.
61. Satoh J, Tabunoki H, Arima K: **Molecular network analysis suggests aberrant CREB-mediated gene regulation in the Alzheimer disease hippocampus.** *Dis Markers* 2009, **27**(5):239-252.
62. Farmer P, Pugin J: **Beta-adrenergic agonists exert their "anti-inflammatory" effects in monocytic cells through the I κ B/NF- κ B pathway.** *Am J Physiol Lung Cell Mol Physiol* 2000, **279**(4):L675-682.
63. Gavriluk V, Dello Russo C, Heneka MT, Pelligrino D, Weinberg G, Feinstein DL: **Norepinephrine increases I κ B α expression in astrocytes.** *J Biol Chem* 2002, **277**(33):29662-29668.
64. Heneka MT, Gavriluk V, Landreth GE, O'Banion MK, Weinberg G, Feinstein DL: **Noradrenergic depletion increases inflammatory responses in brain: effects on I κ B and HSP70 expression.** *J Neurochem* 2003, **85**:387-398.
65. Norris JG, Benveniste EN: **Interleukin-6 production by astrocytes: induction by the neurotransmitter norepinephrine.** *J Neuroimmunol* 1993, **45**(1-2):137-145.
66. Schlachetzki JC, Fiebich BL, Haake E, de Oliveira AC, Candelario-Jalil E, Heneka MT, Hüll M: **Norepinephrine enhances the LPS-induced expression of COX-2 and secretion of PGE2 in primary rat microglia.** *J Neuroinflammation* 2010, **7**:2.
67. Tomozawa Y, Yabuuchi K, Inoue T, Satoh M: **Participation of cAMP and cAMP-dependent protein kinase in beta-adrenoceptor-mediated interleukin-1 beta mRNA induction in cultured microglia.** *Neurosci Res* 1995, **22**(4):399-409.
68. Juric DM, Miklic S, Carman-Krzan M: **Monoaminergic neuronal activity up-regulates BDNF synthesis in cultured neonatal rat astrocytes.** *Brain Res* 2006, **1108**(1):54-62.
69. Ivy AS, Rodriguez FG, Garcia C, Chen MJ, Russo-Neustadt AA: **Noradrenergic and serotonergic blockade inhibits BDNF mRNA activation following exercise and antidepressant.** *Pharmacol Biochem Behav* 2003, **75**(1):81-88.
70. Cirelli C, Tononi G: **Differential expression of plasticity-related genes in waking and sleep and their regulation by the noradrenergic system.** *J Neurosci* 2000, **20**(24):9187-9194.
71. Chen MJ, Nguyen TV, Pike CJ, Russo-Neustadt AA: **Norepinephrine induces BDNF and activates the PI-3K and MAPK cascades in embryonic hippocampal neurons.** *Cell Signal* 2007, **19**(1):114-128.
72. Murer MG, Yan Q, Raisman-Vozari R: **Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease.** *Prog Neurobiol* 2001, **63**:71-124.
73. Bekinschtein P, Cammarota M, Izquierdo I, Medina JH: **BDNF and memory formation and storage.** *Neuroscientist* 2008, **14**(2):147-156.
74. Hock C, Heese K, Hulette C, Rosenberg C, Otten U: **Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas.** *Arch Neurol* 2000, **57**(6):846-851.
75. Narisawa-Saito M, Wakabayashi K, Tsuji S, Takahashi H, Nawa H: **Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease.** *Neuroreport* 1996, **7**(18):2925-2928.
76. Phillips HS, Hains JM, Armanini M, Laramée GR, Johnson SA, Winslow JW: **BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease.** *Neuron* 1991, **7**(5):695-702.
77. Fukumoto N, Fujii T, Combarros O, Kamboh MI, Tsai SJ, Matsushita S, Nacmias B, Comings DE, Arboleda H, Ingelsson M, et al: **Sexually dimorphic effect of the Val66Met polymorphism of BDNF on susceptibility to Alzheimer's disease: New data and meta-analysis.** *Am J Med Genet B Neuropsychiatr Genet* 2010, **153B**:235-242.
78. Weinschenker D: **Functional consequences of locus coeruleus degeneration in Alzheimer's disease.** *Curr Alzheimer Res* 2008, **5**(3):342-345.
79. Cohen Z, Molinatti G, Hamel E: **Astroglial and vascular interactions of noradrenaline terminals in the rat cerebral cortex.** *J Cereb Blood Flow Metab* 1997, **17**(8):894-904.
80. Scheibel AB, Duong TH, Tomiyasu U: **Denervation microangiopathy in senile dementia, Alzheimer type.** *Alzheimer Dis Assoc Disord* 1987, **1**(1):19-37.
81. Kalinin S, Feinstein DL, Xu HL, Huesa G, Pelligrino DA, Galea E: **Degeneration of noradrenergic fibres from the locus coeruleus causes tight-junction disorganisation in the rat brain.** *Eur J Neurosci* 2006, **24**(12):3393-3400.
82. Traver S, Salthun-Lassalle B, Marien M, Hirsch EC, Colpaert F, Michel PP: **The neurotransmitter noradrenaline rescues septal cholinergic neurons in culture from degeneration caused by low-level oxidative stress.** *Mol Pharmacol* 2005, **67**:1882-1891.
83. Troadec JD, Marien M, Darios F, Hartmann A, Ruberg M, Colpaert F, Michel PP: **Noradrenaline provides long-term protection to dopaminergic neurons by reducing oxidative stress.** *J Neurochem* 2001, **79**(1):200-210.
84. Madrigal JL, Leza JC, Polak P, Kalinin S, Feinstein DL: **Astrocyte-derived MCP-1 mediates neuroprotective effects of noradrenaline.** *J Neurosci* 2009, **29**(1):263-267.
85. Xiao Z, Deng PY, Rojanathammanee L, Yang C, Grisanti L, Permpoonputtana K, Weinschenker D, Doze VA, Porter JE, Lei S: **Noradrenergic depression of neuronal excitability in the entorhinal cortex via activation of TREK-2 K⁺ channels.** *J Biol Chem* 2009, **284**(16):10980-10991.
86. Echeverria V, Clerman A, Dore S: **Stimulation of PGE receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following beta-amyloid exposure.** *Eur J Neurosci* 2005, **22**(9):2199-2206.
87. Koriyama Y, Chiba K, Mohri T: **Propentofylline protects beta-amyloid protein-induced apoptosis in cultured rat hippocampal neurons.** *Eur J Pharmacol* 2003, **458**(3):235-241.
88. Counts SE, Mufson EJ: **Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity.** *J Neurochem* 2010, **113**(3):649-660.
89. Sun L, Wang X, Liu S, Wang Q, Wang J, Bennecib M, Gong CX, Sengupta A, Grundke-Iqbal I, Iqbal K: **Bilateral injection of isoproterenol into hippocampus induces Alzheimer-like hyperphosphorylation of tau and spatial memory deficit in rat.** *FEBS Lett* 2005, **579**(1):251-258.

90. Marien MR, Colpaert FC, Rosenquist AC: **Noradrenergic mechanisms in neurodegenerative diseases: a theory.** *Brain Res Rev* 2004, **45**:38-78.
91. Eikelenboom P, van Exel E, Hoozemans JJ, Veerhuis R, Rozemuller AJ, van Gool WA: **Neuroinflammation - an early event in both the history and pathogenesis of Alzheimer's disease.** *Neurodegener Dis* 2010, **7**(1-3):38-41.

Pre-publication history

The pre-publication history for this paper can be accessed here:
<http://www.biomedcentral.com/1471-2350/11/162/prepub>

doi:10.1186/1471-2350-11-162

Cite this article as: Combarros *et al.*: The dopamine β -hydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis Project. *BMC Medical Genetics* 2010 **11**:162.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

